Lupus & antiphospholipid syndrome
Comorbidity Development and Mortality During 10 Years of Follow-up in a Danish Nationwide Cohort of 3178 Patients With Systemic Lupus Erythematosus
Authors' conclusion
The study provides a comprehensive overview of risk estimates and the timing of comorbidities and mortality in a nationwide cohort of adult patients with SLE.
Study context
- Population
- Adults with newly diagnosed systemic lupus erythematosus (SLE) in Denmark, 1996–2018, and matched population comparators (84.3% female; mean age 47.4 years)matched cohort
- Participants
- 3,178 vs 60,090
- Exposure
- Newly diagnosed SLE vs matched population comparators
- SLEn = 3,178
- Population comparatorsn = 60,090reference
- Outcome
- Incidence of comorbidities and mortality (incidence rates per 1000 person-years and age- and sex-adjusted IRRs) in year 1, year 2, years 3-5 and years 6-10 after SLE diagnosis
Methodological details19 age- and sex-matched population comparators per patient, national Danish registries, age- and sex-adjusted incidence rate ratios (IRRs)
- 19 age- and sex-matched population comparators per patient
- National Danish registries
- Age- and sex-adjusted IRRs
Main finding
As reported in the abstract
Mortality risk (times increased)
4.1
first year of follow-up
Mortality risk (times increased)
1.6- to 2.1
subsequent follow-up periods
Observational data: associations, not effects.
Original publication
Comorbidity Development and Mortality During 10 Years of Follow-up in a Danish Nationwide Cohort of 3178 Patients With Systemic Lupus Erythematosus. J Rheumatol. Published 1 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →